On Thursday, Following Stocks were among the “Top 100 Gainers” of U.S. Stock Market: Celladon Corporation (NASDAQ:CLDN), Juno Therapeutics Inc. (NASDAQ:JUNO), Guess’ Inc. (NYSE:GES), Kite Pharma, Inc. (NASDAQ:KITE)
Celladon Corporation (NASDAQ:CLDN), with shares inclined 17.20%, closed at $27.26.
Juno Therapeutics Inc. (NASDAQ:JUNO), with shares jumped 17.18%, settled at $59.68.
Guess’ Inc. (NYSE:GES), with shares climbed 16.01%, and closed at $19.42.
Kite Pharma, Inc. (NASDAQ:KITE), surged 15.73%, and closed at $73.51.
Latest NEWS regarding these Stocks are depicted underneath:
Celladon Corporation (NASDAQ:CLDN)
In the start of this week, Celladon Corporation (CLDN), declared that on March 9, 2015 the Compensation Committee of the Corporation’s Board of Directors approved the grant of inducement stock options to purchase a total of 40,000 shares of ordinary stock to three new employees, with two of such grants having a grant date of March 9, 2015 (the “March 9 Grants”) and the third having a grant date of March 11, 2015 (the “March 11 Grant”), with each such grant date corresponding to the employees’ respective hire dates.
Each of the March 9 Grants has an exercise price per share equal to $24.89, the fair market value on the grant date of the March 9 Grants. The March 11 Grant has an exercise price per share equal to $25.99, the fair market value on the grant date of the March 11 Grant. Each stock option vests over the course of four years, with 25% vesting on the one-year anniversary of the employee’s first day of employment with the Corporation and 1/48 of the shares vesting monthly thereafter, subject to the new employee’s continued service relationship with the Corporation on each such date. Each stock option has a ten year term and is subject to the terms and conditions of the Corporation’s 2013 Equity Incentive Plan and applicable stock option contract.
Each of the stock options was granted as an inducement material to the new employees entering into employment with Celladon Corporation in accordance with NASDAQ listing Rule 5635(c)(4).
Celladon Corporation, a clinical-stage biotechnology corporation, focuses on developing treatments for heart failure, diabetes, and neurodegenerative diseases. The corporation’s lead product candidate comprises MYDICAR that uses genetic enzyme replacement therapy to correct the Sarco/endoplasmic reticulum Ca 2+ -ATPase 2a enzyme deficiency in heart failure patients that results in inadequate pumping of the heart.
Juno Therapeutics Inc. (NASDAQ:JUNO)
Juno Therapeutics Inc. (JUNO), stated business highlights and financial results for the fourth quarter and year ended December 31, 2014.
“During the past year, we have made noteworthy progress in building a world class science and clinical organization. We have leveraged our CAR and TCR technology platform to continue to develop cellular therapeutics with the potential to meaningfully improve the lives of patients with cancer,” said Hans Bishop, Juno’s Chief Executive Officer. “Our successful rounds of private financing, together with our IPO, have offered us with the financial resources that we need to continue advancing our product candidates. Within the next 12 months, we expect to have 10 product candidates in clinical development directed at six different cancer-associated antigens.”
Juno anticipates to burn between $125 million and $150 million in cash in 2015, not including cash inflows or outflows from business development activities and ongoing litigation.
“Juno enters 2015 financially strong and prepared to support the initiation of clinical trials for multiple product candidates targeting an array of antigens, our planned Phase II trial of JCAR015, and other milestones,” said Steven M. Harr, M.D., Chief Financial Officer of Juno. “Our financial guidance for 2015 provides evidence of our commitment to patients and to investors to deliver on our business strategy, to spend prudently, and to invest in the innovation and development of therapies that re-engage the immune system to fight cancer.”
Juno Therapeutics, Inc. is building a fully integrated biopharmaceutical corporation focused on revolutionizing medicine by re-engaging the body’s immune system to treat cancer. Founded on the vision that the use of human cells as therapeutic entities will drive one of the next important phases in medicine, Juno is developing cell-based cancer immunotherapies based on chimeric antigen receptor and high-affinity T cell receptor technologies to genetically engineer T cells to recognize and kill cancer. Juno is developing multiple cell-based product candidates to treat a variety of B-cell malignancies in addition to solid tumors.
Guess’ Inc. (NYSE:GES)
Guess’ Inc. (GES), stated unaudited financial results for its fourth quarter and fiscal year ended January 31, 2015.
For the fourth quarter of fiscal 2015, the Corporation recorded net earnings of $53.9 million, a 24.1% decrease contrast to adjusted net earnings of $71.1 million for the fourth quarter of fiscal 2014. Diluted earnings per share reduced 24.1%, to $0.63, contrast to adjusted diluted earnings per share of $0.83 for the preceding-year quarter. The preceding-year adjusted net earnings excluded restructuring charges of $2.1 million ($1.4 million net of taxes). On a GAAP basis, preceding-year fourth quarter net earnings were $69.6 million and diluted earnings per share totaled $0.82, counting an unfavorable $0.01 after-tax influence from the restructuring charges.
Paul Marciano, Chief Executive Officer, commented, “Overall fourth quarter results were in line with our expectations. In North America, we were happy by the emerging trends, as comps and traffic improved in the back-end of the quarter. Our E-commerce business continues to show strength, with 37% growth in the quarter and almost $80 million in proceeds for the full year. In terms of products, our Marciano line resonated very well with our customers, posting double digit positive comps in the quarter, and our handbags and footwear also performed well.”
Mr. Marciano continued, “Turning to the outlook for fiscal year 2016, currencies will definitely be a headwind if they stay at current levels. But, as always, we will remain focused on what we can control, like our North America real estate realignment, providing a unique customer experience within our stores, and tightly managing our costs and inventory levels. We will continue investing in our omni-channel strategy globally and expect it to be a growth vehicle for fiscal 2016. We will also continue to leverage the Marciano brand in our North America Guess stores, and I am very confident in our forthcoming product lines for fiscal 2016. Of course, all of these efforts are done with two key priorities in mind: improve the profitability of the Corporation while at the same time protecting our key asset, the Guess Brand.”
Guess?, Inc. designs, markets, distributes, and licenses lifestyle collections of contemporary apparel and accessories for men, women, and children that reflect the American lifestyle and European fashion sensibilities.
Kite Pharma, Inc. (NASDAQ:KITE)
Kite Pharma, Inc. (KITE), a clinical-stage biopharmaceutical corporation focused on developing engineered autologous T cell therapy (eACT(TM)) products based on CAR and TCR gene therapy platforms for the treatment of cancer, recently declared that it has further strengthened its TCR product platform and established a European presence through the attainment of T-Cell Factory B.V. (TCF(TM)), a privately held Dutch corporation, which has been renamed Kite Pharma EU. Founded by preeminent scientists, counting Professor Dr. Ton N. M. Schumacher, Ph.D., of the Netherlands Cancer Institute (NKI) and Professor Dr. Dirk H. Busch, M.D., of the Technische Universitat Munchen (TUM), TCF has the ability to discover and develop tumor-specific TCRs for broad application in cancer treatment based on its proprietary TCR-GENErator(TM) platform. Professor Schumacher will assume the role of Chief Scientific Officer of Kite Pharma EU, and maintain his position as Deputy Director of the NKI. Through this attainment, Kite Pharma has obtained license contracts with IBA GmbH, Sanquin Blood Supply Foundation, and the NKI that comprise rights to certain new intellectual property in the TCR space developed by Professor Schumacher at the NKI. In addition, the attainment provides access to European clinical manufacturing facilities, launching a base for Kite to build its global presence and initiate clinical programs in the EU.
The attainment of TCF follows the declaration earlier this month of Kite’s expanded Cooperative Research and Development Contract (CRADA) with the National Cancer Institute (NCI) to develop new TCR candidates, counting against tumor neo-antigens, truly tumor-specific antigens generated as tumors accumulate genetic mutations. TCRs broaden the approach to cancer treatment by allowing targeting of tumor antigens found inside cancer cells, in addition to surface antigens.
Financial terms of Kite’s attainment of TCF comprise an upfront payment of up to EURO20.0M (about $21.0M USD) to TCF shareholders, licensors and employees, of which EURO3.8M (about $4.0M USD) will be paid in Kite stock. Kite is obligated to make certain milestone payments upon the achievement of clinical, regulatory and sales milestones regarding TCR-based product candidates.
Kite Pharma, Inc. operates a clinical-stage biopharmaceutical corporation which focuses on the development and commercialization of novel cancer immunotherapy products. Kite is based in Santa Monica, CA.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
